BIOMAT Database Logo BIOMAT Database Logo

Subacute hepatic failure associated with a new antidiabetic agent, troglitazone: a case report with autopsy examination. 2000

M Fukano, and S Amano, and J Sato, and K Yamamoto, and H Adachi, and H Okabe, and Y Fujiyama, and T Bamba
Second Department of Internal Medicine, Shiga University of Medical Science, Japan.

An autopsy case of fatal subacute hepatic failure after administration of troglitazone is described. The liver dysfunction developed about five months after the patient, a sixty-three-year-old woman, had been initially treated with troglitazone. The patient developed hepatic failure and died despite various hepatic auxiliary treatments such as plasmapheresis. Autopsy findings revealed focal liver cell necrosis, cholestasis and steatosis with infiltration of lymphocytes and neutrophils and lack of regenerative activity. The causative mechanism of liver dysfunction may be metabolite aberration, as a result of accumulation of hepatotoxic metabolite(s), in a category of idiosyncratic liver injury. It is proposed to monitor liver function strictly and periodically for the diabetic patients prescribed troglitazone.

UI MeSH Term Description Entries
D007004 Hypoglycemic Agents Substances which lower blood glucose levels. Antidiabetic,Antidiabetic Agent,Antidiabetic Drug,Antidiabetics,Antihyperglycemic,Antihyperglycemic Agent,Hypoglycemic,Hypoglycemic Agent,Hypoglycemic Drug,Antidiabetic Agents,Antidiabetic Drugs,Antihyperglycemic Agents,Antihyperglycemics,Hypoglycemic Drugs,Hypoglycemic Effect,Hypoglycemic Effects,Hypoglycemics,Agent, Antidiabetic,Agent, Antihyperglycemic,Agent, Hypoglycemic,Agents, Antidiabetic,Agents, Antihyperglycemic,Agents, Hypoglycemic,Drug, Antidiabetic,Drug, Hypoglycemic,Drugs, Antidiabetic,Drugs, Hypoglycemic,Effect, Hypoglycemic,Effects, Hypoglycemic
D008875 Middle Aged An adult aged 45 - 64 years. Middle Age
D009336 Necrosis The death of cells in an organ or tissue due to disease, injury or failure of the blood supply.
D002839 Chromans Benzopyrans saturated in the 2 and 3 positions. Dihydrobenzopyrans
D003924 Diabetes Mellitus, Type 2 A subclass of DIABETES MELLITUS that is not INSULIN-responsive or dependent (NIDDM). It is characterized initially by INSULIN RESISTANCE and HYPERINSULINEMIA; and eventually by GLUCOSE INTOLERANCE; HYPERGLYCEMIA; and overt diabetes. Type II diabetes mellitus is no longer considered a disease exclusively found in adults. Patients seldom develop KETOSIS but often exhibit OBESITY. Diabetes Mellitus, Adult-Onset,Diabetes Mellitus, Ketosis-Resistant,Diabetes Mellitus, Maturity-Onset,Diabetes Mellitus, Non-Insulin-Dependent,Diabetes Mellitus, Slow-Onset,Diabetes Mellitus, Stable,MODY,Maturity-Onset Diabetes Mellitus,NIDDM,Diabetes Mellitus, Non Insulin Dependent,Diabetes Mellitus, Noninsulin Dependent,Diabetes Mellitus, Noninsulin-Dependent,Diabetes Mellitus, Type II,Maturity-Onset Diabetes,Noninsulin-Dependent Diabetes Mellitus,Type 2 Diabetes,Type 2 Diabetes Mellitus,Adult-Onset Diabetes Mellitus,Diabetes Mellitus, Adult Onset,Diabetes Mellitus, Ketosis Resistant,Diabetes Mellitus, Maturity Onset,Diabetes Mellitus, Slow Onset,Diabetes, Maturity-Onset,Diabetes, Type 2,Ketosis-Resistant Diabetes Mellitus,Maturity Onset Diabetes,Maturity Onset Diabetes Mellitus,Non-Insulin-Dependent Diabetes Mellitus,Noninsulin Dependent Diabetes Mellitus,Slow-Onset Diabetes Mellitus,Stable Diabetes Mellitus
D005260 Female Females
D006801 Humans Members of the species Homo sapiens. Homo sapiens,Man (Taxonomy),Human,Man, Modern,Modern Man
D000077288 Troglitazone A chroman and thiazolidinedione derivative that acts as a PEROXISOME PROLIFERATOR-ACTIVATED RECEPTORS (PPAR) agonist. It was formerly used in the treatment of TYPE 2 DIABETES MELLITUS, but has been withdrawn due to hepatotoxicity. 5-(4-((6-Hydroxy-2,5,7,8-tetramethylchroman-2-yl-methoxy)benzyl)-2,4-thiazolidinedione) - T,CS 045,CS-045,Prelay,Rezulin,CS045
D013844 Thiazoles Heterocyclic compounds where the ring system is composed of three CARBON atoms, a SULFUR and NITROGEN atoms. Thiazole
D017093 Liver Failure Severe inability of the LIVER to perform its normal metabolic functions, as evidenced by severe JAUNDICE and abnormal serum levels of AMMONIA; BILIRUBIN; ALKALINE PHOSPHATASE; ASPARTATE AMINOTRANSFERASE; LACTATE DEHYDROGENASES; and albumin/globulin ratio. (Blakiston's Gould Medical Dictionary, 4th ed) Hepatic Failure

Related Publications

M Fukano, and S Amano, and J Sato, and K Yamamoto, and H Adachi, and H Okabe, and Y Fujiyama, and T Bamba
Troglitazone (CS-045): a new antidiabetic agent.
May 1997, Hormone and metabolic research = Hormon- und Stoffwechselforschung = Hormones et metabolisme,
M Fukano, and S Amano, and J Sato, and K Yamamoto, and H Adachi, and H Okabe, and Y Fujiyama, and T Bamba
Troglitazone, a new antidiabetic agent, decreases cyclosporine level.
November 1998, The Journal of heart and lung transplantation : the official publication of the International Society for Heart Transplantation,
M Fukano, and S Amano, and J Sato, and K Yamamoto, and H Adachi, and H Okabe, and Y Fujiyama, and T Bamba
Troglitazone: an antidiabetic agent.
May 1998, American journal of health-system pharmacy : AJHP : official journal of the American Society of Health-System Pharmacists,
M Fukano, and S Amano, and J Sato, and K Yamamoto, and H Adachi, and H Okabe, and Y Fujiyama, and T Bamba
Troglitazone-associated hepatic failure.
February 2000, The American journal of gastroenterology,
M Fukano, and S Amano, and J Sato, and K Yamamoto, and H Adachi, and H Okabe, and Y Fujiyama, and T Bamba
Troglitazone-associated hepatic failure.
February 1999, Annals of internal medicine,
M Fukano, and S Amano, and J Sato, and K Yamamoto, and H Adachi, and H Okabe, and Y Fujiyama, and T Bamba
Rodent carcinogenicity with the thiazolidinedione antidiabetic agent troglitazone.
July 2002, Toxicological sciences : an official journal of the Society of Toxicology,
M Fukano, and S Amano, and J Sato, and K Yamamoto, and H Adachi, and H Okabe, and Y Fujiyama, and T Bamba
Troglitazone-induced hepatic failure leading to liver transplantation. A case report.
July 1998, Annals of internal medicine,
M Fukano, and S Amano, and J Sato, and K Yamamoto, and H Adachi, and H Okabe, and Y Fujiyama, and T Bamba
Troglitazone-induced fulminant hepatitis: report of a case with autopsy findings.
January 2000, Journal of diabetes and its complications,
M Fukano, and S Amano, and J Sato, and K Yamamoto, and H Adachi, and H Okabe, and Y Fujiyama, and T Bamba
Effect of troglitazone, a new oral antidiabetic agent, on fructose-induced insulin resistance.
October 1995, Hormone and metabolic research = Hormon- und Stoffwechselforschung = Hormones et metabolisme,
M Fukano, and S Amano, and J Sato, and K Yamamoto, and H Adachi, and H Okabe, and Y Fujiyama, and T Bamba
Chronic toxicity in monkeys with the thiazolidinedione antidiabetic agent troglitazone.
February 2002, The Journal of toxicological sciences,
Copied contents to your clipboard!